Company profile
NXI Therapeutics company profile
NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical and early clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives.
Business identity
- Website
- https://nxitherapeutics.com
- Contact email
- [email protected]
- Phone number
- +41 612077110
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0+
- Founded
- 2021-01-01, Year
Headquarters
- Headquarters
- Breíl, Grisons, Switzerland
- Postal code
- 4056
- Country code
- CH
- Continent
- Europe